Neuronetics, Inc. Supplemental Financial and Operating Information

For the period ended September 30, 2024

Revenue ($ thousands)	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2022 FY	2023 FY
Total U.S. NeuroStar Advanced Therapy System Revenues	$3,642	$4,382	$3,934	$4,616	$3,850	$4,489	$3,597	$4,524	$3,310	$4,000	$4,108	$16,575	$16,460
YoY Change	108%	70%	51%	64%	6%	2%	-9%	-2%	-14%	-11%	14%	70%	-1%
Total U.S. Treatment Sessions Revenues	$9,469	$11,295	$11,864	$12,450	$10,643	$12,314	$13,060	$14,879	$12,988	$11,660	$13,326	$45,077	$50,896
YoY Change	-2%	5%	16%	11%	12%	9%	10%	20%	22%	-5%	2%	7%	13%
Total U.S. Other Revenues	$406	$455	$446	$447	$471	$486	$554	$469	$495	$470	$488	$1,754	$1,980
YoY Change	-3%	6%	9%	-10%	16%	7%	24%	5%	5%	-3%	-12%	0%	13%
Total U.S. Revenues	$13,517	$16,132	$16,244	$17,513	$14,964	$17,289	$17,211	$19,872	$16,793	$16,130	$17,922	$63,406	$69,336
YoY Change	15%	17%	22%	20%	11%	7%	6%	13%	12%	-7%	4%	19%	9%
Total International Revenues	$664	$198	$253	$686	$576	$321	$673	$442	$624	$320	$608	$1,800	$2,012
YoY Change	36%	-50%	-51%	47%	-13%	62%	166%	-36%	8%	0%	-10%	-3%	12%
Total Revenues	$14,181	$16,329	$16,498	$18,199	$15,540	$17,610	$17,884	$20,313	$17,417	$16,450	$18,530	$65,206	$71,348
YoY Change	15%	15%	20%	21%	10%	8%	8%	12%	12%	-7%	4%	18%	9%

U.S. Operating and Financial Metrics	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2022 FY	2023 FY
Total NeuroStar Systems	46	59	50	58	49	54	43	58	40	49	48	213	204
YoY Change	100%	64%	25%	21%	7%	-8%	-14%	0%	-18%	-9%	12%	45%	-4%
Average Revenue Per Active Site ($) (1)	$9,874	$11,280	$11,364	$11,517	$9,667	$11,391	$11,916	$13,238	$11,300	$10,000	$11,390		
YoY Change	-6%	-6%	2%	-5%	-2%	1%	5%	15%	17%	-12%	-4%		

(1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period)